EMA Management Board endorses work program for 2014

18 December 2013

The European Medicines Agency’s Management Board, at its meeting on December 11-12, adopted the Agency’s work program and budget for 2014.

In addition to delivering core business activities to a high level of quality and consistency, implementing new legislations and increasing transparency and communication, the EMA said, new priorities for 2014 include:

enhancing cooperation within the European medicines network through training, expansion of national experts programmes and IT systems that deliver value to the network;
facilitating early stages of medicines development by promoting and integrating the range of procedures available to medicine developers;
improving the quality, integration and accessibility of data held by the Agency for the network and stakeholders;
reinforcing international cooperation with emphasis on inspection cooperation and capability building to ensure that clinical trials conducted outside the European Union and medicines destined for EU citizens are of the required high quality;
tackling the issue of antimicrobial resistance and availability of anti-infective treatment options both in the human and veterinary areas; and
improving operational effectiveness and efficiency of the Agency as part of its reorganization.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >